Show simple item record

dc.contributor.authorPuri, Rajiv*
dc.contributor.authorPalit, V.*
dc.contributor.authorLoadman, Paul M.*
dc.contributor.authorFlannigan, G. Michael*
dc.contributor.authorShah, T.K.*
dc.contributor.authorChoudry, G.A.*
dc.contributor.authorBasu, Saurajyoti*
dc.contributor.authorDouble, John A.*
dc.contributor.authorLenaz, G.*
dc.contributor.authorChawla, S.*
dc.contributor.authorBeer, M.*
dc.contributor.authorKalken, C.V.*
dc.contributor.authorde Boer, R.*
dc.contributor.authorBeijnen, J.H.*
dc.contributor.authorTwelves, Christopher J.*
dc.contributor.authorPhillips, Roger M.*
dc.date.accessioned2009-12-17T17:01:31Z
dc.date.available2009-12-17T17:01:31Z
dc.date.issued2006
dc.identifier.citationPuri R, Palit V, Loadman PM, et al (2006) Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. Journal of Urology. 176(4): 1344-1348.en
dc.identifier.urihttp://hdl.handle.net/10454/4150
dc.descriptionNoen
dc.description.abstractThe quinone based bioreductive drug apaziquone (EO9) failed to demonstrate efficacy in previous phase II studies following intravenous administration. We determined the dose of apaziquone that can be safely administered intravesically and explored its activity for superficial bladder transitional cell carcinoma. Six patients with multifocal, Ta/T1 and G1/G2 transitional cell carcinoma of the bladder received escalating doses of apaziquone formulated as EOquin¿ (0.5 mg/40 ml up to 16 mg/40 ml) weekly for 6 weeks. A further 6 patients received weekly apaziquone at the highest nontoxic dose established. Pharmacokinetic parameters were determined in urine and blood, and the pharmacodynamic markers NQO1 (reduced nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase-1) and glucose transporter 1 were also characterized. Efficacy was determined against a marker lesion. Local toxicity (grades 2 and 3 dysuria, and hematuria) was observed at doses of 8 mg/40 ml and above but 4 mg/40 ml was well tolerated with no systemic or local side effects. Apaziquone in urine increased linearly with the dose but no apaziquone was detected in plasma. In 8 of 12 patients complete macroscopic and histological disappearance of the marker lesion occurred. A correlation between response and NQO1 and/or glucose transporter 1 expression could not be established. Intravesical administration of 4 mg/40 ml apaziquone was well tolerated and had ablative activity against superficial bladder cancer marker lesions.en
dc.language.isoenen
dc.relation.isreferencedbyhttp://dx.doi.org/10.1016/j.juro.2006.06.047en
dc.subjectEO9en
dc.subjectBladderen
dc.subjectCarcinomaen
dc.subjectBladder Neoplasmsen
dc.subjectTransitional Cellen
dc.titlePhase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Canceren
dc.status.refereedYesen
dc.typeArticleen
dc.type.versionNo full-text available in the repositoryen


This item appears in the following Collection(s)

Show simple item record